Myriad Genetics Intangible Assets

Myriad Genetics (MYGN) currently reports a intangible assets of $150M as of March 2026. That compares with $260M in the prior-year period — down 43.4% year over year. Use the charts on this page to explore Myriad Genetics's intangible assets history and peer comparisons.

Myriad Genetics's intangible assets decreased from $260M to $150M — a 43.4% year-over-year decrease (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Myriad Genetics reported $150M in intangible assets as of March 2026. That compares with $260M in the prior-year period — down 43.4% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current intangible assets of $150M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Myriad Genetics, and consider following MYGN for alerts when major investors trade the stock.

Myriad Genetics is classified in the Healthcare sector. On intangible assets, it currently shows $150M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing MYGN with unrelated industries.